Get the Stockscreener App
10.77
0.37%
0.04
Myriad Genetics Inc stock is traded at $10.77, with a volume of 260.99K.
It is up +0.37% in the last 24 hours and down -15.66% over the past month.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
See More
Previous Close:
$10.73
Open:
$10.85
24h Volume:
260.99K
Relative Volume:
0.25
Market Cap:
$986.04M
Revenue:
$823.60M
Net Income/Loss:
$-116.00M
P/E Ratio:
-8.2846
EPS:
-1.3
Net Cash Flow:
$-107.30M
1W Performance:
-21.84%
1M Performance:
-15.66%
6M Performance:
-60.78%
1Y Performance:
-51.44%
1-Day Range:
$10.59
$10.90
1-Week Range:
$9.76
$12.28
52-Week Range:
$9.76
$29.30
Myriad Genetics Inc Stock (MYGN) Company Profile
Name
Myriad Genetics Inc
Sector
Industry
Phone
801-584-3600
Address
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Compare MYGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
10.76 | 986.04M | 823.60M | -116.00M | -107.30M | -1.30 |
|
TMO
Thermo Fisher Scientific Inc
|
525.74 | 198.19B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
207.72 | 148.92B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
128.25 | 36.52B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IDXX
Idexx Laboratories Inc
|
439.88 | 35.63B | 3.90B | 887.87M | 798.08M | 10.67 |
|
IQV
Iqvia Holdings Inc
|
188.27 | 33.12B | 15.41B | 1.37B | 2.11B | 7.50 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-25 | Initiated | Craig Hallum | Buy |
| Dec-10-24 | Initiated | UBS | Neutral |
| Dec-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-19-24 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-27-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-03-24 | Resumed | Jefferies | Underperform |
| May-08-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-21-23 | Resumed | Piper Sandler | Neutral |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Jul-05-23 | Resumed | JP Morgan | Underweight |
| May-23-23 | Upgrade | Goldman | Sell → Buy |
| Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-06-22 | Initiated | Stephens | Equal-Weight |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Sell |
| Sep-26-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Aug-14-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-02-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Aug-01-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Jul-29-19 | Downgrade | Needham | Strong Buy → Hold |
| Jul-09-19 | Downgrade | Cowen | Outperform → Market Perform |
| Mar-12-19 | Reiterated | Needham | Strong Buy |
| Jan-03-19 | Initiated | Needham | Strong Buy |
| Nov-30-18 | Upgrade | Goldman | Sell → Neutral |
| Oct-10-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jul-11-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-21-18 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jan-29-18 | Initiated | Goldman | Sell |
| Jan-22-18 | Reiterated | Barclays | Equal Weight |
| Jan-05-18 | Initiated | BTIG Research | Buy |
| Oct-02-17 | Resumed | Leerink Partners | Mkt Perform |
| Aug-09-17 | Reiterated | Barclays | Equal Weight |
| Feb-08-17 | Upgrade | Ladenburg Thalmann | Sell → Neutral |
| Jan-18-17 | Initiated | Deutsche Bank | Sell |
| Oct-10-16 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
View All
Myriad Genetics Inc Stock (MYGN) Latest News
Myriad Genetics Faces Financial Uncertainty Amid Potential Tax Law Changes - TipRanks
Myriad Genetics (NASDAQ:MYGN) Announces Quarterly Earnings Results - MarketBeat
Myriad Genetics (NASDAQ:MYGN) Lowered to Hold Rating by StockNews.com - MarketBeat
Myriad Genetics (NASDAQ:MYGN) Sets New 12-Month Low on Disappointing Earnings - MarketBeat
Myriad Genetics (NASDAQ:MYGN) Earns "Outperform" Rating from Raymond James - MarketBeat
UBS Group Has Lowered Expectations for Myriad Genetics (NASDAQ:MYGN) Stock Price - MarketBeat
Leerink Partnrs Forecasts Myriad Genetics Q2 Earnings - MarketBeat
Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools - GlobeNewswire
Myriad Genetics Partners With Gabbi To Offer Breast Cancer Risk Assessment & Care Solution - Nasdaq
Myriad Genetics Collaborates with Gabbi to Enhance Breast Cancer Risk Assessment and Care Services - Nasdaq
How Myriad Genetics' New Telehealth Partnership Could Transform Breast Cancer Detection - StockTitan
Here's What Analysts Are Forecasting For Myriad Genetics, Inc. (NASDAQ:MYGN) After Its Yearly Results - Simply Wall St
Myriad Genetics price target lowered to $19 from $27 at Raymond James - MSN
Myriad Genetics Full Year 2024 Earnings: EPS Misses Expectations - Yahoo Finance
Myriad Genetics stock hits 52-week low at $10.05 amid challenges By Investing.com - Investing.com South Africa
Liquid Biopsy Market Worth US$11.3 billion at a robust CAGR of 11.9% | MarketsandMarkets™. - GlobeNewswire Inc.
Myriad Genetics Reports Strong Growth Amid Challenges - TipRanks
Myriad Genetics (MYGN) Stock Drops Due to Disappointing Results - GuruFocus.com
Myriad Genetics Faces Cost Restructuring As UnitedHealthcare Ends GeneSight Coverage, Appoints New CEO - Benzinga
Why Myriad Genetics (MYGN) Shares Are Plunging Today - Financial Content
Myriad Genetics stock hits 52-week low at $10.05 amid challenges - Investing.com
Myriad Genetics, Inc. (MYGN): AI-Driven Precision Medicine for Prostate Cancer - Insider Monkey
Myriad Genetics (MYGN) Meets Q4 Earnings Estimates - MSN
MYGN Q4 Earnings Meet Estimates, Revenues Rise Y/Y, Stock Down - Yahoo Finance
Myriad Genetics, Inc. (NASDAQ:MYGN) Q4 2024 Earnings Call Transcript - Insider Monkey
Myriad Genetics Appoints Sam Raha as Chief Executive -February 25, 2025 at 05:17 am EST - Marketscreener.com
Myriad Genetics Shares Drop On Wider Q4 Loss, Q1 Loss Outlook; Names New CEO - RTTNews
Myriad Genetics Q4 Adjusted Earnings Decline, Revenue Increases; Full-Year Guidance Reiterated - Marketscreener.com
Myriad (MYGN) Reports Q4 Earnings: What Key Metrics Have to Say - MSN
Myriad Genetics Inc (MYGN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Myriad Genetics Reports Strong Revenue Growth in 2024 - TipRanks
Hold Rating on Myriad Genetics Amid Leadership Transition and Adjusted Revenue Expectations - TipRanks
Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio - GlobeNewswire
Myriad Genetics names new CEO and COO for future growth By Investing.com - Investing.com Australia
Earnings call transcript: Myriad Genetics Q4 2024 sees steady revenue growth - Investing.com
MYRIAD GENETICS Earnings Results: $MYGN Reports Quarterly Earnings - Nasdaq
Myriad Genetics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Myriad Genetics Reports Q4 Revenue of $211 Million, Slightly Mis - GuruFocus.com
Myriad: Q4 Earnings Snapshot - CTPost
Top 8 Trending AI News Updates Investors Should Not Miss - Insider Monkey
Myriad Genetics Appoints Sam Raha As President And CEO -February 24, 2025 at 05:07 pm EST - Marketscreener.com
Myriad Genetics Announces CEO Transition in 2025 - TipRanks
Myriad Genetics CEO Paul Diaz to Return to Cressey & Co. - MarketWatch
Myriad Genetics names new CEO and COO for future growth - Investing.com India
Myriad Genetics (NASDAQ:MYGN) Misses Q4 Sales Targets, Stock Drops - Yahoo Finance
Myriad Genetics Announces Senior Leadership Transition - The Manila Times
Myriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results; Full-year 2024 revenue of $838 million grew 11% year-over-year, the second consecutive year of double-digit revenue growth - The Manila Times
(MYGN) Myriad Genetics Expects Fiscal Year 2025 Adjusted EPS Range $0.07$0.11 - Marketscreener.com
Earnings Flash (MYGN) Myriad Genetics, Reports Q4 Revenue $210.6M, vs. FactSet Est of $211.6M - Marketscreener.com
Myriad Genetics Reports Fourth Quarter and Full-Year 2024 - GlobeNewswire
Can Myriad Genetics' New CEO Accelerate Growth in Precision Medicine? - StockTitan
Myriad Genetics Inc Stock (MYGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.07%
2.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):